ArticlePloS one2023
Exploring spatial variations and the individual and contextual factors of uptake of measles-containing second dose vaccine among children aged 24 to 35 months in Ethiopia.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Uptake of the Second Dose of the Measles Vaccine and Its Determinants Among Children Aged Less Than 5 Years: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2025Pooled it
- Coverage and determinants of second-dose measles vaccination among under-five children in East Africa countries: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Article
- Timeliness of the second dose of measles-containing vaccine uptake and its determinants among children aged 24-36 months in Gondar City, Northwest Ethiopia, 2023: Community-based cross-sectional study design.Journal of virus eradication · 2025Article
- Article
- Review
- Application of Geographic Information Systems (GIS) in the Study of Prostate Cancer Disparities: A Systematic Review.Cancers · 2024Review
- Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of Ethiopia.Vaccines · 2024Article
- Measles second dose vaccine uptake and its associated factors among children aged 24-35 months in Northwest Ethiopia, 2022.Scientific reports · 2024Article
- Second dose of measles-containing vaccine coverage and associated factors among children aged 24-36 months in Gondar city, Central Gondar, Northwest Ethiopia, 2023.Frontiers in public health · 2024Article
- Spatial variation and predictors of incomplete pneumococcal conjugate vaccine (PCV) uptake among children aged 12-35 months in Ethiopia: spatial and multilevel analyses.Frontiers in public health · 2024Article
- Predictors for low coverage of uptake of second dose of measles vaccine among children in sub-Saharan Africa, 2023: a systematic review and meta-analysis.Journal of pharmaceutical policy and practice · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo eliminate measles, which is a devastating contagious disease, Ethiopia introduced the measles-containing second dose vaccine (MCV2) that will be given in the second year of life. Despite its paramount benefit, the coverage was low worldwide and, in Ethiopia, there is scarce evidence on the geographic variations and factors associated with uptake of MCV2.
objectiveThis study aimed to explore the spatial variations and the individual and contextual factors of uptake of measles-containing second dose vaccine among children aged 24 to 35 months in Ethiopia.
methodsWe used the 2019 Ethiopian Mini Demographic and Health Survey data. A total weighted sample of 800 children aged 24 to 35 months was used. Multilevel analysis was employed and an adjusted odds ratio (AOR) with a 95% confidence interval (CI) was reported. Factors with a p-value<0.05 in the multivariable analysis were declared to be significant predictors of MCV2 uptake. To explore the spatial variations of MCV2 uptake, we have conducted spatial analysis using both Arc GIS version 10.7 and SaTScan version 9.6 software.
resultsThe proportion of MCV2 uptake was 9.84% (95% CI: 7.96%, 12.11%). Children whose mothers were aged 20-34 years (AOR = 0.19; 95%CI: 0.05, 0.69) and 35-49 years (AOR = 0.21; 95%CI: 0.04, 0.90), being the 4th-5th child (AOR = 4.02; 95%CI: 1.45, 11.14) and 6th and above child (AOR = 4.12; 95%CI: 1.42, 13.05) and children who did not receive full childhood vaccinations (AOR = 0.44; 95%CI: 0.25, 0.77) were significantly associated with MCV2 uptake. Besides, MCV2 uptake was clustered in Ethiopia (Global Moran's I = 0.074, p-value <0.01). The primary cluster spatial window was detected in the Benishangul-Gumuz region with LLR = 10.05 and p = 0.011.
conclusionThe uptake of MCV2 in Ethiopia was low. Maternal age, birth order, and uptake of the other basic vaccines were associated with MCV2 uptake. Besides, MCV2 uptake was clustered in Ethiopia and the primary cluster spatial window was located in the Benishangul-Gumuz region. Therefore, special concern should be given to regions with lower MCV2 uptake such as the Benishangul-Gumuz region. Besides, it is better to give attention to basic vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.